Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background of the Problem Viral warts result from infection of the skin or mucous membranes by human papillomavirus (HPV). Some patients develop refractory cases due to abnormal immune function, persistent viral presence, or recurrent warts. The clinical challenge in treating refractory viral warts lies in the limited effectiveness of single therapeutic approaches, high recurrence rates, and the fact that a significant proportion of patients are infected with high-risk or special HPV subtypes. These factors necessitate combined multi-modal treatments and genetic etiological screening.
Current Treatment Status Thermotherapy (44°C ± 2°C, 30 minutes per session): Studies have demonstrated that it can stimulate the activation of local immune cells (such as Langerhans cells), thereby enhancing antiviral immune responses.
Hydrogen peroxide: It possesses antibacterial properties and promotes tissue repair. In keratinocytes, it can induce thermally induced pyroptosis, thereby enhancing the efficacy of antiviral treatment.
HPV genotyping Refractory viral warts are often associated with infection by specific high-risk or low-risk HPV subtypes (e.g., HPV 16, 18, 2, 4, etc.). HPV genotype is closely linked to treatment outcomes and recurrence rates.
Relevant pathogenic gene screening This involves exploring intrinsic patient susceptibility, such as genetic polymorphisms related to immune function (e.g., HLA typing or Toll-like receptor-related genes). It also includes screening for rare gene mutations, such as mutations in the GATA2, IL2RG, and DOCK8 genes, which lead to impaired viral clearance and a propensity to develop multiple viral warts.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trial group | Experimental | Local hyperthermia combined with hydrogen peroxide |
|
| Control group | Placebo Comparator | Local hyperthermia combined with normal saline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| An infrared hyperthermia device | Device | (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) An infrared hyperthermia device was used to apply local hyperthermia at 44°C to the target warts(largest and most severe warts).The device includes a heating source, an infrared temperature monitor, an adjusting arm, a control circuit for temperature stabilization, and a display. It uses a tungsten-halogen lamp (wavelength: 760-2300 nm, peak at 1200 nm) to maintain the temperature of a 0.5*0.5 cm skin area within ±0.1°C using a non-contact infrared feedback system.Hyperthermia: Conduct 44-degree Celsius, 30-minute sessions. Do it daily for the first 3 days, then 2 sessions every 7 days for 24 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Complete clearance rate of warts within 6 months | The complete clearance rate was defined as the proportion of patients with lesions that completely disappeared within 6 months of completing all treatments. | 6 months after the first time of treatment. |
| Recurrence rate of warts | Recurrence was the proportion of patients with recurrence of lesions at the cured lesion site within 6 and 12 months after treatment. | recurrence was the proportion of patients with reappearance of lesions at previously cleared sites within 6,12 months after treatment. |
| Complete clearance rate of warts within 3 months | The complete clearance rate was defined as the proportion of patients with lesions that completely disappeared within 3 months of completing all treatments. | 3 months after the first time of treatment. |
| HPV genotyping | Collect the tissue sample from the wart for HPV gene testing. | Pre-treatment and 3,6 months after the first time of treatment |
| Pathogenic Gene Screening Analysis | Collecting patient blood samples for pathogenic gene screening | Pre-treatment |
| Immune-related cytokines | Collecting the patient's blood samples to test immune-related cytokines | Pre-treatment and 3,6 months after the first time of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in the size and number of warts at different points in time | Changes in the size and number of warts at different time points (1 week, 2 weeks, 3 weeks, 4 weeks, 12 weeks, 24 weeks) | At 1 week, 2 weeks, 3 weeks, 4 weeks, 12 weeks, 24 weeks follow-up |
| Curative effect of different types of warts |
Not provided
Inclusion Criteria:
- 1: Patients with a disease course of ≥2 years who have failed to respond to ≥2 treatment methods (such as topical ointments, cryotherapy, laser therapy, etc.)
2: The subject or their legal guardian is able to understand and sign the informed consent form/agree to participate in the study.
Exclusion Criteria:
1: The subject or their legal guardian is unable to understand and refuses to sign the informed consent form / refuses to participate in the study
2: Individuals allergic to local hyperthermia or hydrogen peroxide;
3: Subjects with tumors or other serious diseases are unable to complete this clinical study;
4: Due to personal or other objective reasons, it is not possible to ensure timely treatment and follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xinghua Gao | Contact | 024-83282524 | gaobarry@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) | Recruiting | Shenyang | Liaoning | 110001 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000084462 | Hyperthermia |
| D014860 | Warts |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D018882 | Heat Stress Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D006861 | Hydrogen Peroxide |
| D012996 | Solutions |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D010545 | Peroxides |
| D010087 | Oxides |
| D000838 | Anions |
| D007477 | Ions |
| D004573 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Hydrogen Peroxide 3 % Topical Solution | Drug | Dressing: Dress with a cotton ball soaked in 3% hydrogen peroxide one hour prior to each hyperthermia session. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts. |
|
| Normal Saline (NS) | Drug | The control group used normal saline as the placebo for wet compress, and the hyperthermia treatment was the same as that of the trial group. |
|
The cure of different types of warts (common warts, plantar warts, condyloma acuminatum) was followed up at 6 months. |
| followed up at 6 months. |
| Occurrence of adverse events | occurrence of adverse events (short - and long-term adverse reactions) (e.g. blisters, erythema, nail changes, ulcers/scars, hyperpigmentation, hypopigmentation, erosion) | During treatment and follow-up |
| Treatment-related pain intensity | Pain assessed by Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain) | During each treatment session (Day 1, 2, 3, 10, 11, 18, 19, 26, ....180) |
| Patient satisfaction score | Self-reported satisfaction on a 5-point Likert scale (0=very dissatisfied, 5=very satisfied) | At 6-month follow-up |
|
| Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) | Recruiting | Shenyang | Liaoning | China |
| D014947 | Wounds and Injuries |
| D030361 | Papillomavirus Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D017193 | Skin Diseases, Viral |
| D014412 | Tumor Virus Infections |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| Electrolytes |
| D007287 | Inorganic Chemicals |
| D017382 | Reactive Oxygen Species |
| D005609 | Free Radicals |
| D017601 | Oxygen Compounds |
| D009930 | Organic Chemicals |
| D004364 | Pharmaceutical Preparations |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |